CLEVELAND, Oct. 29, 2018 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) today announced a collaboration with GenesisCare,
the largest provider of cancer services in the UK, Spain and Australia, to introduce the first MRIdian
MRI-guided radiotherapy system in the UK to benefit cancer
patients.
As part of the formal agreement, multiple MRIdian linear
accelerators will be deployed within the GenesisCare network, with
the first two systems to be installed in the UK. MRIdian leverages
the soft-tissue imaging capabilities of MRI to allow oncologists to
visualize tumors and personalize treatment more accurately than is
possible with conventional technology. The agreement will allow
GenesisCare to advance its vision of precision radiation medicine
by contributing to the evidence base for, and delivering, high
quality image-guided, adaptive radiotherapy.
"GenesisCare is continually exploring how technology can help us
to deliver better outcomes for people with cancer," said
Aldo Rolfo, Executive Manager for
GenesisCare Europe. "Combining an MRI scanner with a linear
accelerator is the way of the future in radiotherapy, allowing us
to see – for the first time – what's really happening inside the
body during treatment. This will enable our clinicians to offer
truly personalized radiotherapy by adapting treatment in real-time,
to better target tumors and minimize side effects for
patients."
With more than 130 oncology and cardiology centers in total,
GenesisCare offers radiotherapy at 12 centers in the United Kingdom, 21 centers in Spain and 30 centers in Australia. Every year more than 160,000 people
from around the world receive care through GenesisCare's team of
more than 2,500 highly trained healthcare professionals and support
staff.
"We're excited to partner with GenesisCare to bring the
important clinical benefits of MRIdian MRI-guided radiotherapy to
cancer patients in the UK and around the world," said Scott Drake, President and CEO of ViewRay. "The
reach of the GenesisCare network is vast and their investment in
MRIdian is a testament to its industry leading innovation for
on-table adaptive therapy. We are proud to be revolutionizing the
field of radiation oncology."
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the
MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purpose
built to address specific challenges, including beam distortion,
skin toxicity, and other concerns that potentially may arise when
high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. These statements are subject to risks
and uncertainties that could cause future results to differ
materially from those referenced. Forward looking statements
include, but are not limited to references to future MRIdian
installations, clinical value and outcomes. Given these
uncertainties, the reader is advised not to place any undue
reliance on any forward-looking statements. Additional risk factors
include, among others, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates, government and regulatory
uncertainty, including but not limited to obtaining authorizations
to market and new tariffs and trade restrictions, and overall
market conditions. These forward-looking statements are made as of
the date of this press release, and ViewRay assumes no obligation
to update the forward-looking statements, or to update the reasons
why actual results differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available at
www.sec.gov.
About GenesisCare
GenesisCare delivers treatment to people with cancer and heart
disease, the two largest disease burdens globally. We're committed
to leading the change in how care is designed and given, and are
currently leading or participating in more than 100 clinical
trials.
The organisation employs more than 2,500 highly trained
healthcare professionals and support staff across Australia, Europe and now China, including some of the world's most
experienced specialists. Every year GenesisCare clinical teams see
more than 160,000 people at more than 130 locations. For cancer
treatment, that includes 12 centres in the UK, 21 in Spain and 30 in Australia, with more than 20 new centres under
development. We also offer cardiology and sleep services at more
than 80 locations across Australia.
Our purpose is to design care experiences that get the best
possible life outcomes. We believe that care should be focused on
the individual, not the condition, and are proud of our patient
satisfaction ratings, which place us in the top 1 per cent of
outpatient healthcare organisations in the world. For more
information visit www.genesiscare.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-signs-agreement-with-genesiscare-to-bring-the-first-mridian-mri-guided-radiotherapy-systems-to-the-uk-300739072.html
SOURCE ViewRay, Inc.